Login to Your Account



NASH data 'Intercept'-ed by plan to publish; FLINT lock won't open at liver meeting

By Randy Osborne
Staff Writer

Wednesday, October 8, 2014
The stellar top-line data unveiled in January from Intercept Pharmaceuticals Inc.'s phase IIb obeticholic acid trial known as FLINT in nonalcoholic steatohepatitis helped the shares to a near 300 percent gain and whetted investor appetite for the full results, but it looks like they'll have to wait longer.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription